The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Implantable ...

Doctors at Columbus Community Hospital now have a high-tech new tool that can help them diagnose irregular heart rhythms that may not show up during standard testing. The tool, called a cardiac loop ...

DUBLIN--(BUSINESS WIRE)--The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac Centers and Other ...

www.benzinga.com ...